NeoPL-HPL

Human platelet lysate (HPL) has emerged as a promising alternative to fetal bovine serum (FBS) for the in vitro expansion of chondrocytes. Compared to FBS, HPL offers several key advantages: it is safer for clinical applications under current Good Manufacturing Practice (cGMP) conditions, as it eliminates the risk of animal pathogen transmission and the presence

Human platelet lysate (hPL) is a key component in cell culture media, rich in factors that influence cell viability, migration, and secretory potential. It has replaced animal-derived serum like fetal bovine serum (FBS) due to safety concerns, such as the risk of zoonotic disease transmission. Studies have also highlighted hPL’s impact on MSC morphology and

Blood derivatives have emerged as FBS alternatives, with human plasma, serum, and platelet concentrates (lysates or serum-converted) being studied for MSC-based cell therapy production.Platelet concentrates have become essential in MSC production, offering cost-effective, large-scale, and standardized supplement production. Human platelet lysate (hPL) is a powerful xeno-free supplement that promotes cell growth, survival, proliferation, and maintains

The researchers identified factors including immunomodulatory molecules (IL-10, IL-6, TGF-alpha, GM-CSF, G-CSF), the RANTES chemokine, and growth factors (IGF-1, VEGF-A, PDGF-AA, PDGF-AB, basic FGF, EGF, and TGFβ) that play roles in cell stimulation, differentiation, maintenance, and growth. These factors were found to be significantly higher in platelet-derived preparations compared to FBS. The concentrations of soluble

They found that hPL promoted faster BMSC proliferation and higher calcium content and alkaline phosphatase activity compared to FCS, especially in the early stages of differentiation. These results suggest hPL can replace FCS in culture media without affecting osteogenic differentiation. According to the research, cells cultured in 10% hPL-supplemented expansion medium exhibited significantly higher (p

  hPL supplementation leads to more consistent osteoclastic differentiation of MCs compared to 10% FBS. In co-cultures, hPL allows resorption, especially at low concentrations. High concentrations of hPL promote osteogenic differentiation and bone-like matrix formation in MSC cultures and co-cultures. The research highlights that hPL not only accelerates osteogenic differentiation of mesenchymal stromal cells (MSCs)